Temporal trends in viral SetPoint and peak CD4 cell count soon after HIV-1 seroconversion

Objectives: To examine whether HIV-1 virulence, as measured by prognostic markers soon after seroconversion, has changed over time and across subgroups in the context of widespread ART availability. Design: Observational cohort study of individuals with well-estimated HIV-1 seroconversion dates recruited from clinics in eight European countries and Canada (CASCADE Collaboration). Methods: We analyzed data from 21,933 participants who seroconverted 1980–2014, while ART-naïve and AIDS-free. Piecewise linear mixed models with one knot at 1 year after seroconversion for log 10 HIV-1 RNA (setpoint viral load, SPVL) and 4 months for square-root CD4 cell count (peak CD4) were fitted. Models adjusted for age, sex/probable exposure route, region of origin, diagnosis during acute infection, and assay type. Results: SPVL increased and peak CD4 declined over time until approximately 2000, then stabilized, with a mild reversal after 2005. Estimated (95% CI) average SPVL for those seroconverting on 1/1/1980, 1/1/1995, 1/1/2005, and 31/12/2014 was 3.2 (3.0–3.4), 4.0 (3.9–4.1), 4.3 (4.2–4.4), and 4.2 (4.1–4.3) log10 copies/mL, respectively. Corresponding estimates for peak CD4 were 960 (898–1025), 615 (584–648), 521 (492–551), and 560 (526–594) cells/μL. The increase in SPVL up to 2005 was less pronounced in European/North American MSM (1.0 log 10 copies/mL) than in men and women with heterosexual exposure from the same region or from Africa (1.5 and 1.4 log 10 copies/mL, respectively). Conclusions: SPVL and peak CD4 stabilized by 2000–2005, consistent with HIV-1 adaptation to the population. The subsequent trend reversal, most evident among MSM, warrants ongoing monitoring.